

# Blanca Xicoy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2535807/publications.pdf>

Version: 2024-02-01

127  
papers

3,033  
citations

218381

26  
h-index

174990

52  
g-index

142  
all docs

142  
docs citations

142  
times ranked

3602  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplantation, 2022, 57, 416-422.  | 1.3 | 11        |
| 2  | Monocyte subset distribution in myeloproliferative and myelodysplastic/myeloproliferative neoplasms with monocytosis. Leukemia Research, 2022, 112, 106771.  | 0.4 | 1         |
| 3  | Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Hla, 2022, 99, 93-104.  | 0.4 | 3         |
| 4  | Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. Cancer, 2022, 128, 2441-2448.  | 2.0 | 14        |
| 5  | Chronic myelomonocytic leukemia and blastic plasmacytoid dendritic cell neoplasm. A case report and systematic review. Cytometry Part B - Clinical Cytometry, 2021, 100, 292-295.  | 0.7 | 5         |
| 6  | Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach. Cancers, 2021, 13, 841.  | 1.7 | 5         |
| 7  | Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. Lancet Haematology, 2021, 8, e194-e204.  | 2.2 | 39        |
| 8  | Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. British Journal of Haematology, 2021, 194, 708-717.  | 1.2 | 7         |
| 9  | Mutational profile and relative telomere length in Chronic Myelomonocytic Leukemia subgroups according to the 2016 World Health Organization classification. Leukemia Research, 2021, 111, 106726.   | 0.4 | 0         |
| 10 | Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients. HemaSphere, 2021, 5, e657.  | 1.2 | 2         |
| 11 | Comparison of flow-FISH and MM-qPCR telomere length assessment techniques for the screening of telomeropathies. Annals of the New York Academy of Sciences, 2020, 1466, 93-103.  | 1.8 | 35        |
| 12 | Impact of previous admission to an intensive care unit on stem cell transplantation outcome. Medicina Clínica, 2020, 155, 382-387.   | 0.3 | 1         |
| 13 | Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model. Biology of Blood and Marrow Transplantation, 2020, 26, 2237-2244. | 2.0 | 14        |
| 14 | Tratamiento actual de las neoplasias mieloproliferativas: frente a tres escenarios. Medicina Clínica, 2020, 154, 131-133.  | 0.3 | 0         |
| 15 | Polycythemia Vera Evolution to Chronic Myelomonocytic Leukemia: The Prognostic Value of Next Generation Sequencing. HemaSphere, 2020, 4, e466.   | 1.2 | 4         |
| 16 | Distinct mutational pattern of myelodysplastic syndromes with and without 5q treated with lenalidomide. British Journal of Haematology, 2020, 189, e133-e137.  | 1.2 | 4         |
| 17 | Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. Blood, 2020, 136, 1851-1862.  | 0.6 | 112       |
| 18 | Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial. Blood, 2020, 136, 28-29.   | 0.6 | 8         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Sequential Study By RNA-Seq Shows a Reduction in Inflammation and a Cell Cycle Activation in T-Lymphocytes from Myelodysplastic Syndrome with Del(5q) after Lenalidomide Treatment in Patients Included in the "Sintra-REV" Clinical Trial. <i>Blood</i> , 2020, 136, 26-27.  | 0.6 | 0         |
| 20 | Myelodysplastic Syndromes with 20q Deletion: Incidence, Prognostic Value and Impact on Response to Azacitidine of <i>ASXL1</i> Chromosomal Deletion and Genetic Mutations. <i>Blood</i> , 2020, 136, 1-2.   | 0.6 | 0         |
| 21 | Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2019, 94, E264-E267.  | 2.0 | 17        |
| 22 | Immediate Effects of Dasatinib on the Migration and Redistribution of Na <sup>+</sup> ve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients. <i>Frontiers in Pharmacology</i> , 2019, 10, 1340.  | 1.6 | 11        |
| 23 | Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018, 93, E152-E154.  | 2.0 | 11        |
| 24 | Segundas neoplasias en pacientes adultos receptores de un trasplante de progenitores hematopoyéticos. <i>Medicina Clínica</i> , 2018, 150, 421-427.   | 0.3 | 0         |
| 25 | DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features. <i>Epigenetics</i> , 2018, 13, 8-18.   | 1.3 | 14        |
| 26 | Indications and use of, and incidence of major bleeding with, antithrombotic agents in myelodysplastic syndrome. <i>Leukemia Research</i> , 2018, 73, 24-28.  | 0.4 | 2         |
| 27 | The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS. <i>Leukemia Research</i> , 2018, 70, 34-36.                                  | 0.4 | 15        |
| 28 | Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine. <i>Oncotarget</i> , 2018, 9, 19342-19355.  | 0.8 | 15        |
| 29 | Utilidad del lavado broncoalveolar y la citometría de flujo en pacientes con hemopatías malignas e insuficiencia respiratoria. <i>Medicina Clínica</i> , 2017, 148, 297-302.  | 0.3 | 0         |
| 30 | Inspecting Targeted Deep Sequencing of Whole Genome Amplified DNA Versus Fresh DNA for Somatic Mutation Detection: A Genetic Study in Myelodysplastic Syndrome Patients. <i>Biopreservation and Biobanking</i> , 2017, 15, 360-365.   | 0.5 | 0         |
| 31 | Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group. <i>American Journal of Hematology</i> , 2017, 92, E534-E541.                                       | 2.0 | 6         |
| 32 | Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R). <i>American Journal of Hematology</i> , 2017, 92, 614-621. | 2.0 | 12        |
| 33 | Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features. <i>Oncotarget</i> , 2016, 7, 57021-57035.   | 0.8 | 26        |
| 34 | Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases. <i>American Journal of Hematology</i> , 2016, 91, 185-192.   | 2.0 | 18        |
| 35 | Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2016, 97, 33-38.   | 1.1 | 23        |
| 36 | International Sentinel Site Surveillance of Patients with Transfusional Hemosiderosis Treated with Deferasirox in Actual Practice Setting. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S85.  | 0.2 | 0         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. <i>Modern Pathology</i> , 2016, 29, 1541-1551.  | 2.9 | 11        |
| 38 | Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2016, 34, 3284-3292.  | 0.8 | 20        |
| 39 | Highly variable mutational profile of <i>ASXL1</i> in myelofibrosis. <i>European Journal of Haematology</i> , 2016, 97, 331-335.  | 1.1 | 6         |
| 40 | Long-term results of prednisone treatment for the anemia of myelofibrosis. <i>Leukemia and Lymphoma</i> , 2016, 57, 120-124.  | 0.6 | 16        |
| 41 | Safety and Efficacy of Dasatinib Treatment Change for Patients Previously Treated with Imatinib with Late Warning Response. Results from the Phase II, Open, Multicenter Dasapost Study. <i>Blood</i> , 2016, 128, 5450-5450.   | 0.6 | 1         |
| 42 | Analysis of Transfusion Dependency Development and Disease Evolution in Patients with MDS with 5q- and without Transfusion Needs at Diagnosis. <i>Blood</i> , 2016, 128, 3180-3180.   | 0.6 | 1         |
| 43 | Considering Bone Marrow Blasts from Nonerythroid Cellularity Improves the Prognostic Evaluation of MDS in the Context of IPSS-R and Permits a Better Risk Assessment of MDS Patients Classified into the Intermediate Risk Category. <i>Blood</i> , 2016, 128, 3185-3185.                       | 0.6 | 0         |
| 44 | Application of Trusight Myeloid Panel on Whole Genome Amplified DNA in Myelodysplastic Syndrome Patients. <i>Blood</i> , 2016, 128, 5519-5519.  | 0.6 | 0         |
| 45 | Comparison of the Molecular Spectrum of Lenalidomide-Treated Myelodysplastic Syndrome with and without Del(5q). <i>Blood</i> , 2016, 128, 3172-3172.  | 0.6 | 0         |
| 46 | Treatment Outcomes in Patients with Transfusional Hemosiderosis Who Received Deferasirox for up to 3 Years: Results from Sentinel Study. <i>Blood</i> , 2016, 128, 4834-4834.   | 0.6 | 0         |
| 47 | Considering Bone Marrow Blasts from Nonerythroid Cells Improves the Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts. <i>Blood</i> , 2016, 128, 1991-1991.   | 0.6 | 0         |
| 48 | Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2015, 100, 17-22.  | 1.7 | 43        |
| 49 | Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older. <i>European Journal of Haematology</i> , 2015, 95, 576-582.  | 1.1 | 6         |
| 50 | Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. <i>Leukemia</i> , 2015, 29, 1875-1881.   | 3.3 | 93        |
| 51 | Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score. <i>Leukemia Research</i> , 2015, 39, 52-57.  | 0.4 | 18        |
| 52 | Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction. <i>Leukemia Research</i> , 2015, 39, 296-306.   | 0.4 | 50        |
| 53 | Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study. <i>Cancer</i> , 2015, 121, 423-431. | 2.0 | 34        |
| 54 | Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis. <i>Annals of Hematology</i> , 2015, 94, 947-954.   | 0.8 | 31        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Co-existence of <i>JAK2</i> V617F and <i>CALR</i> mutations in primary myelofibrosis. <i>Leukemia and Lymphoma</i> , 2015, 56, 2973-2974.   | 0.6 | 21        |
| 56 | Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study. <i>Lancet Haematology</i> , 2015, 2, e260-e266.  | 2.2 | 24        |
| 57 | Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML. <i>Leukemia Research</i> , 2015, 39, 1146-1153. | 0.4 | 15        |
| 58 | Calreticulin mutations are not present in patients with myeloproliferative chronic myelomonocytic leukemia. <i>Annals of Hematology</i> , 2015, 94, 869-871.  | 0.8 | 1         |
| 59 | Mutational Studies Using Next Generation Sequencing in High Risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Patients Treated with Azacitidine (High risk MDS 2009 protocol) <i>Tj ETQq1 1 0.784314 rgt /Over</i>  | 0.6 | 0         |
| 60 | Molecular Genetic Profiling in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features. <i>Blood</i> , 2015, 126, 2883-2883.   | 0.6 | 0         |
| 61 | Methylation Patterns in Patients with High-Risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Treated with Azacitidine (high-risk MDS 2009 protocol from CETLAM Group). <i>Blood</i> , 2015, 126, 1682-1682.   | 0.6 | 0         |
| 62 | Efficacy and Safety of Dasatinib in Late Suboptimal Response CML Patients a Its Relation with Lymphocytosis, Lymphocyte Migration and Chemokine Receptor Expression. <i>Blood</i> , 2015, 126, 4015-4015.   | 0.6 | 0         |
| 63 | Results of treatment with azacitidine in patients aged $\geq 75$ years included in the Spanish Registry of Myelodysplastic Syndromes. <i>Leukemia and Lymphoma</i> , 2014, 55, 1300-1303.   | 0.6 | 16        |
| 64 | Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma. <i>European Journal of Haematology</i> , 2014, 93, 487-491.   | 1.1 | 23        |
| 65 | Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. <i>Leukemia and Lymphoma</i> , 2014, 55, 2341-2348.  | 0.6 | 34        |
| 66 | Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. <i>British Journal of Haematology</i> , 2014, 166, 189-201.   | 1.2 | 15        |
| 67 | Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. <i>Annals of Hematology</i> , 2014, 93, 2037-2043.  | 0.8 | 66        |
| 68 | Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis. <i>Leukemia Research</i> , 2014, 38, 304-309.   | 0.4 | 4         |
| 69 | Outcome and management of pregnancies in severe chronic neutropenia patients by the European Branch of the Severe Chronic Neutropenia International Registry. <i>Haematologica</i> , 2014, 99, 1395-1402.   | 1.7 | 31        |
| 70 | The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. <i>Haematologica</i> , 2014, 99, e55-e57.  | 1.7 | 51        |
| 71 | Utility of SNP Arrays in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features or No Metaphases. <i>Blood</i> , 2014, 124, 4659-4659.  | 0.6 | 0         |
| 72 | Advanced Stage Hodgkin's Lymphoma Has More Aggressive Characteristics but Similar Outcome in HIV-Infected Than in HIV-Negative Patients in the Combination Antiretroviral Therapy Era. <i>Blood</i> , 2014, 124, 4435-4435.   | 0.6 | 0         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Survey of Treatment of 1021 Patients with Myelodysplastic Syndromes in a Tertiary Referral Center 2007-2013. <i>Blood</i> , 2014, 124, 4647-4647.   | 0.6 | 0         |
| 74 | Comparison of Three Prognostic Scoring Systems in a Series of 146 Cases of Chronic Myelomonocytic Leukemia (CMML): MD Anderson Prognostic Score (MDAPS), CMML-Specific Prognostic Scoring System (CPSS) and Mayo Prognostic Model. <i>Blood</i> , 2014, 124, 4660-4660.   | 0.6 | 0         |
| 75 | Frequency and Prognosis of JAK2 V617F, Calr, MPL and ASXL1 Mutations in Primary Myelofibrosis. <i>Blood</i> , 2014, 124, 5562-5562.   | 0.6 | 0         |
| 76 | Azacitidine in Older Patients with Acute Myeloid Leukemia (AML) and Adverse Karyotype. Subanalysis from the Alma Study. <i>Blood</i> , 2014, 124, 945-945.  | 0.6 | 0         |
| 77 | Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. <i>Medicina Clínica</i> , 2013, 141, 95-99.   | 0.3 | 10        |
| 78 | Pro-B acute lymphoblastic leukemia in a patient with severe congenital neutropenia: an unusual form of malignant evolution. <i>Leukemia and Lymphoma</i> , 2013, 54, 2325-2327.   | 0.6 | 3         |
| 79 | Pharmacogenetic analysis in the treatment of Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1706-1712.  | 0.6 | 5         |
| 80 | Chronic myelomonocytic leukemia diagnosed by means of mutational analysis in a patient with persistent monocytosis and tuberculosis. <i>Leukemia and Lymphoma</i> , 2013, 54, 2297-2298.  | 0.6 | 1         |
| 81 | Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. <i>Blood</i> , 2013, 121, 3005-3015.   | 0.6 | 251       |
| 82 | Long-term follow up of patients with human immunodeficiency virus infection and advanced stage Hodgkin's lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine. <i>Haematologica</i> , 2013, 98, e85-e86.   | 1.7 | 15        |
| 83 | Analysis Of Transfusion Dependence Development and Disease Evolution In Patients With MDS and Del(5q) and Without Transfusion Needs At Diagnosis. <i>Blood</i> , 2013, 122, 1542-1542.  | 0.6 | 0         |
| 84 | Aplicability Of The Predictive Model Of Response To Erythropoetic Stimulating Agents (ESA) From Myelodysplastic Syndromes (MDS) and Analysis Of Response and Overall Survival (OS) In a Series Of 99 Patients (Pts) With Chronic Myelomonocytic Leukemia (CMML) From The Spanish Registry Of MDS and The Düsseldorf-MDS Registry, Germany. <i>Blood</i> , 2013, 122, 2813-2813.                               | 0.6 | 0         |
| 85 | Whole-Exome Sequencing In Myelodysplastic Syndromes With 5q- and Normal Karyotype. <i>Blood</i> , 2013, 122, 1551-1551.   | 0.6 | 0         |
| 86 | Very Early Molecular Responses During The First Two Months Of Therapy Are Highly Predictive Of Deep Molecular Responses In Newly-Diagnosed Chronic Myeloid Leukemia In Chronic Phase( CML-CP) Patients Treated Upfront With Nilotinib. The Spanish Substudy Of The ENEST1st Trial. <i>Blood</i> , 2013, 122, 5190-5190.   | 0.6 | 0         |
| 87 | Multivariable Time-Dependent Analysis Of The Impact Of 5 Azacitidine In Patients With Lower-Risk Myelodysplastic Syndrome and Unfavorable Specific Lower-Risk Score. <i>Blood</i> , 2013, 122, 2754-2754.   | 0.6 | 0         |
| 88 | Association of JAK2 Mutation Status and Cytogenetic Abnormalities at Diagnosis in Myeloproliferative Neoplasms and Myelodysplastic/Myeloproliferative Neoplasms. <i>American Journal of Clinical Pathology</i> , 2012, 137, 677-678.  | 0.4 | 2         |
| 89 | Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2012, 97, 310-317. | 1.7 | 194       |
| 90 | A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. <i>Blood</i> , 2012, 119, 5221-5228.  | 0.6 | 37        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2012, 159, 311-321.   | 1.2 | 25        |
| 92  | Lack of impact of human immunodeficiency virus infection on the outcome of lymphoma patients transferred to the intensive care unit. <i>Leukemia and Lymphoma</i> , 2012, 53, 1966-1970.  | 0.6 | 8         |
| 93  | Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival. <i>Annals of Hematology</i> , 2012, 91, 1887-1895.                            | 0.8 | 12        |
| 94  | Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. <i>Cancer</i> , 2012, 118, 127-133.   | 2.0 | 43        |
| 95  | Azacitidine As Front-Line Therapy in AML: Results From Spanish National Registry. Alma Study Investigators. <i>Blood</i> , 2012, 120, 3593-3593.  | 0.6 | 3         |
| 96  | Clinical and Biological Characteristics According to the Burden of JAK2V617F Mutated Allele in BCR-ABL Negative MPNs. <i>Blood</i> , 2012, 120, 1437-1437.  | 0.6 | 0         |
| 97  | Characterization of Cytogenetic Abnormalities and Mutations in ASXL1, SRSF2, CBL and JAK2 Genes in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2012, 120, 4809-4809.  | 0.6 | 0         |
| 98  | Age, Performance Status and Plasma Interleukin-10 Levels At Diagnosis: A Triad for Improving Survival Prediction of Patients with Myelodysplastic Syndromes Already Stratified by IPSS-R. Spanish MDS Group (GESMD). <i>Blood</i> , 2012, 120, 3803-3803.                           | 0.6 | 3         |
| 99  | Cytogenetic risk stratification in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2011, 96, 375-383.   | 1.7 | 226       |
| 100 | Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemia. <i>Medicina Clínica</i> , 2011, 136, 323-328.   | 0.3 | 8         |
| 101 | Prognostic Impact of Monosomal Karyotype in Patients with Myelodysplastic Syndrome and Abnormal Karyotype. A Report From the Spanish Group of MDS (GESMD). <i>Blood</i> , 2011, 118, 1724-1724.   | 0.6 | 2         |
| 102 | Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. <i>Blood</i> , 2010, 116, 1205-1210.   | 0.6 | 202       |
| 103 | Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection. <i>Leukemia and Lymphoma</i> , 2010, 51, 2063-2069.   | 0.6 | 16        |
| 104 | Effectiveness of Various Dosage Regimens of Azacitidine In Patients with Myelodysplastic Syndromes: Safety and Efficacy Final Data From the Spanish Azacitidine Compassionate Use Registry. <i>Blood</i> , 2010, 116, 1853-1853.  | 0.6 | 1         |
| 105 | Azacitidine In Compassionate Use: Response to Therapy, Survival, and Prognostic Factors In 200 Patients Diagnosed with MDS or AML. <i>Blood</i> , 2010, 116, 2933-2933.   | 0.6 | 0         |
| 106 | Limited prognostic value of the International Prognostic Score in advanced stage human immunodeficiency virus infection-related Hodgkin lymphoma treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen. <i>Leukemia and Lymphoma</i> , 2009, 50, 1718-1720. | 0.6 | 7         |
| 107 | Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. <i>Leukemia and Lymphoma</i> , 2008, 49, 1752-1761.   | 0.6 | 98        |
| 108 | Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2008, 19, 958-963.   | 0.6 | 182       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. <i>Haematologica</i> , 2007, 92, 191-198.  | 1.7 | 124       |
| 110 | Response to highly active antiretroviral therapy as the only therapy in an HIV-infected patient with interfollicular Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 2058-2059.  | 0.6 | 5         |
| 111 | Outcome and Prognostic Factors in Patients with Hematologic Malignancies Admitted to the Intensive Care Unit: A Single-Center Experience. <i>International Journal of Hematology</i> , 2007, 85, 195-202.   | 0.7 | 59        |
| 112 | Advanced Stage Is the Most Important Prognostic Factor for Survival in Patients with Systemic Acquired Immunodeficiency Syndrome-Related Non-Hodgkin's Lymphoma Treated with CHOP and Highly Active Antiretroviral Therapy. <i>International Journal of Hematology</i> , 2007, 86, 337-342. | 0.7 | 8         |
| 113 | Comparison of Immunohistochemical (IHC) Expression Profile and Prognosis in 98 Patients with Diffuse Large B Cell Non-Hodgkin's Lymphoma (DLBCL) with and without Human Immunodeficiency Virus (HIV) Infection.. <i>Blood</i> , 2007, 110, 4403-4403.                                       | 0.6 | 0         |
| 114 | Systemic thrombotic thrombocytopenic purpura (TTP) following unrelated cord blood transplantation. <i>Leukemia and Lymphoma</i> , 2006, 47, 1173-1175.  | 0.6 | 1         |
| 115 | Nonmyeloablative Stem Cell Transplantation Is an Effective Therapy for Refractory or Relapsed Hodgkin Lymphoma: Results of a Spanish Prospective Cooperative Protocol. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 172-183.  | 2.0 | 135       |
| 116 | Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2006, 78, 061114074547002-???  | 1.1 | 63        |
| 117 | Is There a Role for Autologous Stem-Cell Transplantation (ASCT) in Peripheral T-Cell Lymphoma (PTCL)? Final Results of a Prospective Phase II Study from the GELCAB.. <i>Blood</i> , 2006, 108, 3070-3070.  | 0.6 | 2         |
| 118 | Intensive Chemotherapy (High-Dose CHOP/ESHAP Regimen) Followed by Autologous Stem-Cell Transplantation (ASCT) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL). Results of a Prospective Phase II Study from the GELCAB.. <i>Blood</i> , 2005, 106, 2077-2077.       | 0.6 | 5         |
| 119 | Treatment with Rituximab, CHOP and Highly Active Antiretroviral Therapy (HAART) in AIDS-Related Diffuse Large B-Cell Lymphomas (DLBCL). Study of 60 Patients.. <i>Blood</i> , 2005, 106, 774-774.   | 0.6 | 0         |
| 120 | Outcome and Prognostic Factors in Patients with Hematological Malignancy That Are Admitted to the Intensive Care Unit.. <i>Blood</i> , 2004, 104, 5285-5285.  | 0.6 | 0         |
| 121 | Post-transplant Burkitt's Leukemia or Lymphoma. Study of Five Cases Treated with Specific Intensive Therapy (PETHEMA ALL-3/97 Trial). <i>Leukemia and Lymphoma</i> , 2003, 44, 1541-1543.   | 0.6 | 23        |
| 122 | AA-type Amyloid Tumor as an Unsuspected Cause of Residual Mass in a Patient With Large B-cell Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2002, 43, 681-682.   | 0.6 | 10        |
| 123 | Favorable Impact of Virological Response to Highly Active Antiretroviral Therapy on Survival in Patients with AIDS-related Lymphoma. <i>Leukemia and Lymphoma</i> , 2002, 43, 1837-1842.  | 0.6 | 19        |
| 124 | Effectiveness of Local Radiotherapy in Primary Extranodal Marginal Zone B-cell Lymphoma of MALT or MALT Lymphoma of Conjunctiva: Study of Four Cases. <i>Leukemia and Lymphoma</i> , 2002, 43, 1975-1977.   | 0.6 | 7         |
| 125 | Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease. <i>Aids</i> , 2002, 16, 1973-1976.  | 1.0 | 32        |
| 126 | Allogeneic transplantation of CD34+selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34+ cells?. <i>Blood</i> , 2001, 98, 2352-2357.   | 0.6 | 71        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Lack of impact of human immunodeficiency virus infection on the outcome of lymphoma patients transferred to the intensive care unit. <i>Leukemia and Lymphoma</i> , 0, , 425-430. | 0.6 | 2         |